

June 19, 2026

J-TEC Accelerates European Expansion of "LabCyte" Human Cultured Tissue Models  
**Decision to Establish a Manufacturing and Sales Subsidiary in Germany**

Japan Tissue Engineering Co., Ltd. (Headquarters: Gamagori, Aichi; President: Kazuto Yamada; hereinafter "J-TEC") hereby announces that it has decided to establish a wholly-owned manufacturing and sales subsidiary, "Japan Tissue Engineering Europe GmbH," in the Federal Republic of Germany, to accelerate the European expansion of its "LabCyte" series of human cultured tissue models for research purposes.

1. **Background and Objectives**

In June 2024, the skin sensitization test method "EpiSensA," which utilizes J-TEC's 3D reconstructed human epidermis (RhE), "LabCyte EPI-MODEL24," became the first RhE-based skin sensitization test method in the world to be adopted into the Organization for Economic Co-operation and Development (OECD) Test Guidelines. Following this milestone, J-TEC has been exporting and expanding sales into the European market, where the adoption of alternatives to animal testing is the most advanced globally. However, because these products contain live human cells, they have a short shelf life. Combined with the impact of recent global geopolitical instabilities, J-TEC faced physical constraints in ensuring a broad and stable supply to customers across various European countries.

To fundamentally resolve this issue and respond promptly to customer needs, J-TEC concluded that establishing local manufacturing and sales operations is essential, leading to the decision to set up a subsidiary in Europe. The chosen base, Heidelberg in the Federal Republic of Germany, is located in the heart of Europe, offering an ideal strategic location for building an efficient logistics network across the continent. Furthermore, by partnering with "BioLabs Heidelberg"—a shared laboratory facility equipped with the necessary equipment and instruments for manufacturing LabCyte products—J-TEC expects to establish a swift and robust production system while minimizing initial capital expenditures.

By launching this new site, J-TEC will be able to reliably deliver its products to customers throughout Europe who previously deferred adoption due to transportation risks and shelf-life constraints, thereby accelerating the European expansion of the "LabCyte" series.

2. **Overview of the New Subsidiary**

(1) Company Name	Japan Tissue Engineering Europe GmbH
(2) Location	Heidelberg, Baden-Württemberg, Federal Republic of Germany
(3) Representative	Managing Director: Yoshihide Ninagawa *
(4) Business Activities	-Development, manufacture and distribution of scientific and laboratory products for re-search-use, - Provision of related services, in particular training, consulting and support services in connection with the use of such products.

(5) Capital	EUR 25,000
(6) Shareholding Ratio	J-TEC 100%

\*Note: A separate local proxy/manager (Prokurist) will reside on-site to manage and operate the subsidiary's day-to-day business.

### 3. Future Outlook

Currently, the incorporation process is in its final stages with the support of the Japan External Trade Organization (JETRO), and operations are scheduled to commence within 2026. J-TEC has historically manufactured and sold human cultured tissues for research by applying the advanced cell culture technologies and quality control methodologies cultivated through its development and manufacturing of regenerative medicine products. By fully deploying these core strengths to the new European base, J-TEC will achieve a stable supply of high-quality products. Through this initiative, J-TEC aims to further promote the global trend of utilizing alternatives to animal testing and contribute to the realization of an ethical, sustainable society that respects animal life.

#### About “Japan Tissue Engineering Co., Ltd. (J-TEC)”

J-TEC is a leading regenerative medicine manufacturer driven by the vision of "Creating a Future for Regenerative Medicine," and has been a member of the Teijin Group since March 2021. As a pioneer in Japan's regenerative medicine industry, J-TEC achieved the country's first-ever regulatory approval for a regenerative medicine product in October 2007 with its autologous cultured epidermis "JACE®." J-TEC currently markets five tissue-engineered products, including cultured epidermis, cartilage, and corneal epithelium.

#### About “BioLabs Heidelberg”

BioLabs Heidelberg is a premier incubator for biotechnology startups located in Heidelberg, one of Europe's leading life science hubs. As part of the global BioLabs network, BioLabs Heidelberg provides entrepreneurs with access to an extensive international ecosystem of investors, industry partners, mentors, and scientific experts.



The facility is fully equipped with state-of-the-art research and manufacturing infrastructure and offers flexible laboratory and office space through monthly rental agreements, starting from a single bench. A diverse portfolio of innovative biotech companies currently operates within the site, creating a dynamic and collaborative community. In addition, BioLabs Heidelberg serves as a strategic soft-landing platform for international life science companies entering the European and German markets. <https://www.biolabs.io/heidelberg>

#### 【 Media and General Inquiries 】

Corporate Management Department, Japan Tissue Engineering Co., Ltd.

E-mail : [jtec-info@jpte.co.jp](mailto:jtec-info@jpte.co.jp) TEL : +81-533-66-2020